MX2022015221A - Procesos para preparar un inhibidor de cinasa jano 1 (jak1). - Google Patents
Procesos para preparar un inhibidor de cinasa jano 1 (jak1).Info
- Publication number
- MX2022015221A MX2022015221A MX2022015221A MX2022015221A MX2022015221A MX 2022015221 A MX2022015221 A MX 2022015221A MX 2022015221 A MX2022015221 A MX 2022015221A MX 2022015221 A MX2022015221 A MX 2022015221A MX 2022015221 A MX2022015221 A MX 2022015221A
- Authority
- MX
- Mexico
- Prior art keywords
- preparing
- processes
- jak1 inhibitor
- jak1
- inhibitor
- Prior art date
Links
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 title abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 2
- 108010000837 Janus Kinase 1 Proteins 0.000 abstract 1
- 102000002295 Janus Kinase 1 Human genes 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000003016 phosphoric acids Chemical class 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/26—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24
- B01J31/28—Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups B01J31/02 - B01J31/24 of the platinum group metals, iron group metals or copper
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente solicitud proporciona procesos para preparar 4-[3-(cianometil)-3-(3',5'-dimetil-1H,1'H-4,4'-bipirazol-1-il)aze tidin-1-il]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-metiletil]benz amida, y sal de ácido fosfórico de este, que es útil como inhibidor selectivo de JAK1 (cinasa Jano 1), así como formas de sal e intermedios relacionados con el mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063033618P | 2020-06-02 | 2020-06-02 | |
PCT/US2021/035400 WO2021247668A1 (en) | 2020-06-02 | 2021-06-02 | Processes of preparing a jak1 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022015221A true MX2022015221A (es) | 2023-03-08 |
Family
ID=76601838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022015221A MX2022015221A (es) | 2020-06-02 | 2021-06-02 | Procesos para preparar un inhibidor de cinasa jano 1 (jak1). |
Country Status (18)
Country | Link |
---|---|
US (1) | US11685731B2 (es) |
EP (1) | EP4157831A1 (es) |
JP (1) | JP2023528868A (es) |
KR (1) | KR20230027086A (es) |
CN (1) | CN115836065A (es) |
AR (1) | AR122505A1 (es) |
AU (1) | AU2021283271A1 (es) |
BR (1) | BR112022024632A2 (es) |
CA (1) | CA3184275A1 (es) |
CL (1) | CL2022003363A1 (es) |
CO (1) | CO2022017344A2 (es) |
CR (1) | CR20220612A (es) |
EC (1) | ECSP22091930A (es) |
IL (1) | IL298118A (es) |
MX (1) | MX2022015221A (es) |
PE (1) | PE20231102A1 (es) |
TW (1) | TW202210471A (es) |
WO (1) | WO2021247668A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE043573T2 (hu) | 2013-05-17 | 2019-08-28 | Incyte Corp | Bipirazol só, amely JAK-gátlóként alkalmazható |
WO2019161098A1 (en) | 2018-02-16 | 2019-08-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
AU2021396231A1 (en) | 2020-12-08 | 2023-06-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
MXPA04002243A (es) | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
ATE335490T1 (de) | 2001-10-30 | 2006-09-15 | Novartis Pharma Gmbh | Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
CN103214483B (zh) | 2005-12-13 | 2014-12-17 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
MX2010005300A (es) | 2007-11-16 | 2010-06-25 | Incyte Corp | 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpir imidin-2-aminas como inhibidores de cinasas janus. |
DK2288610T3 (en) | 2008-03-11 | 2016-11-28 | Incyte Holdings Corp | Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS |
CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
JOP20190231A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
BRPI1012159B1 (pt) | 2009-05-22 | 2022-01-25 | Incyte Holdings Corporation | Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos |
DK2432472T3 (da) | 2009-05-22 | 2019-11-18 | Incyte Holdings Corp | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer |
TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
PT2486041E (pt) | 2009-10-09 | 2013-11-14 | Incyte Corp | Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo |
MX2012009541A (es) | 2010-02-18 | 2012-10-01 | Incyte Corp | Derivados de ciclobutano y metilciclobutano como inhibidores de janus cinasa. |
KR102283091B1 (ko) | 2010-03-10 | 2021-07-30 | 인사이트 홀딩스 코포레이션 | Jak1 저해제로서의 피페리딘4일 아제티딘 유도체 |
SG184870A1 (en) | 2010-04-14 | 2012-11-29 | Array Biopharma Inc | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
AR083933A1 (es) | 2010-11-19 | 2013-04-10 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
CA2820109C (en) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
SG192910A1 (en) | 2011-02-24 | 2013-09-30 | Massachusetts Inst Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CA2849169C (en) | 2011-09-22 | 2019-07-02 | Merck Sharp & Dohme Corp. | Pyrazole carboxamides as janus kinase inhibitors |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
SG10201703533VA (en) | 2012-11-01 | 2017-06-29 | Incyte Corp | Tricyclic fused thiophene derivatives as jak inhibitors |
CR20190073A (es) | 2012-11-15 | 2019-04-25 | Incyte Holdings Corp | FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265) |
RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
HUE043573T2 (hu) | 2013-05-17 | 2019-08-28 | Incyte Corp | Bipirazol só, amely JAK-gátlóként alkalmazható |
MX2015015692A (es) | 2013-05-17 | 2016-03-04 | Hoffmann La Roche | Novedosas heteroarildihidropirimidinas, unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de hepatitis b. |
US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
EP3030227B1 (en) | 2013-08-07 | 2020-04-08 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
HUE041456T2 (hu) | 2014-02-28 | 2019-05-28 | Incyte Corp | JAK1 inhibitorok myelodysplasiás szindrómák kezelésére |
CA2947418A1 (en) | 2014-04-30 | 2015-11-05 | Incyte Corporation | Processes of preparing a jak1 inhibitor and new forms thereto |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
PT3233843T (pt) | 2014-12-16 | 2019-11-26 | Novartis Ag | Compostos de ácido isoxazol hidroxámico como inibidores de lxpc |
-
2021
- 2021-06-02 EP EP21734728.5A patent/EP4157831A1/en active Pending
- 2021-06-02 PE PE2022002824A patent/PE20231102A1/es unknown
- 2021-06-02 KR KR1020227045757A patent/KR20230027086A/ko active Search and Examination
- 2021-06-02 IL IL298118A patent/IL298118A/en unknown
- 2021-06-02 JP JP2022574313A patent/JP2023528868A/ja active Pending
- 2021-06-02 AR ARP210101500A patent/AR122505A1/es unknown
- 2021-06-02 CN CN202180048817.4A patent/CN115836065A/zh active Pending
- 2021-06-02 AU AU2021283271A patent/AU2021283271A1/en active Pending
- 2021-06-02 WO PCT/US2021/035400 patent/WO2021247668A1/en unknown
- 2021-06-02 TW TW110119976A patent/TW202210471A/zh unknown
- 2021-06-02 BR BR112022024632A patent/BR112022024632A2/pt unknown
- 2021-06-02 CR CR20220612A patent/CR20220612A/es unknown
- 2021-06-02 MX MX2022015221A patent/MX2022015221A/es unknown
- 2021-06-02 CA CA3184275A patent/CA3184275A1/en active Pending
- 2021-06-02 US US17/337,065 patent/US11685731B2/en active Active
-
2022
- 2022-11-29 CL CL2022003363A patent/CL2022003363A1/es unknown
- 2022-12-01 CO CONC2022/0017344A patent/CO2022017344A2/es unknown
- 2022-12-01 EC ECSENADI202291930A patent/ECSP22091930A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20231102A1 (es) | 2023-07-19 |
IL298118A (en) | 2023-01-01 |
CA3184275A1 (en) | 2021-12-09 |
US20210380563A1 (en) | 2021-12-09 |
CL2022003363A1 (es) | 2023-05-19 |
ECSP22091930A (es) | 2023-02-28 |
US11685731B2 (en) | 2023-06-27 |
CN115836065A (zh) | 2023-03-21 |
WO2021247668A1 (en) | 2021-12-09 |
KR20230027086A (ko) | 2023-02-27 |
CR20220612A (es) | 2023-04-11 |
CO2022017344A2 (es) | 2023-03-07 |
AU2021283271A1 (en) | 2022-12-15 |
EP4157831A1 (en) | 2023-04-05 |
TW202210471A (zh) | 2022-03-16 |
AR122505A1 (es) | 2022-09-14 |
BR112022024632A2 (pt) | 2023-02-28 |
JP2023528868A (ja) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022015221A (es) | Procesos para preparar un inhibidor de cinasa jano 1 (jak1). | |
JP4395823B2 (ja) | アリール及びヘテロアリール置換複素環式尿素を用いたrafキナーゼの阻害 | |
IL157179A0 (en) | Fused heterocyclic compounds | |
NO329181B1 (no) | Symmetrisk og usymmetrisk substituerte difenylureaforbindelser og farmasoytiske preparater som omfatter disse | |
MA33502B1 (fr) | Composés pyrazolopyrimidine inhibiteurs des jak et procédés | |
KR20040010548A (ko) | 신규 화합물 | |
UA84390C2 (ru) | Производные амидов как активаторы глюкокиназы | |
PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
NO326150B1 (no) | Substituerte pyrazolureaforbindelser og farmasoytiske preparater som omfatter disse | |
RS50918B (sr) | Novi estri fluorenkarbonske kiseline, postupak za njihovo pripremanje, kao i njihova upotreba kao lekova | |
BRPI0514865A (pt) | processo para preparar um composto | |
BR0212775A (pt) | Composto de 1,2,4-triazol | |
HUP0103988A2 (en) | New d3-dopamine receptor selective piperazine and piperidine compounds, process for their preparation, their and pharmaceutical compositions containing them | |
WO2006135641A3 (en) | PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE | |
MA29255B1 (fr) | Derives de pyrazole destines a inhiber les kinases dependantes des cyclines (cdk) et les glycogene synthases kinases (gsk) | |
MA49956B1 (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
MX2007013606A (es) | (3,4-dihidro-quinazolin2-il)-(2-ariloxi-etil)-aminas que tienen una actividad en el receptor 5-ht. | |
WO2004106304A3 (en) | 3 - [2- (3-amino-2-oxo-2h-pyridin-1-yl) - acetylamino] - 4- oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
JO2425B1 (en) | Method for manufacturing vinyl acetate acid derivatives | |
MY143245A (en) | 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases | |
HUP0304101A2 (hu) | Pirazolszármazékok, eljárás előállításukra, alkalmazásuk, a vegyületeket tartalmazó gyógyszerkészítmények és intermedierjeik | |
RU2002130710A (ru) | Производное пиридин-1-оксида и способ его преобразования в фармацевтически эффективные соединения | |
JP4365681B2 (ja) | 2−アミノ−4−ヘテロアリールエチル−チアゾリン誘導体および誘導型noシンターゼの阻害剤としてのその使用 | |
WO2000046214A1 (en) | Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them | |
ES8601928A1 (es) | Un metodo de preparar fenilalquil(piperazinil u homopiperazinil)propil-(ureas o tioureas)sustituidas) |